NetworkNewsBreaks – Anavex Life Sciences (AVXL) Reports Positive Data for ANAVEX 2-73 in Patients with Alzheimer’s; Shares Higher
Anavex Life Sciences (NASDAQ: AVXL) this morning issued a positive update from its phase 2a study of ANAVEX 2-73 in patients with mild-to-moderate Alzheimer’s disease. At 41 weeks, Alzheimer’s patients showed a stabilization of cognitive and functional measures taking a daily oral dosing between 10mg and 50mg of ANAVEX 2-73 in the exploratory clinical trial. The company notes the significance of this data, as current therapeutics are only able to temporarily slow the worsening of dementia symptoms rather than prevent disease progression. ANAVEX 2-73 was well tolerated, and there were no serious adverse events or clinically significant treatment-related adverse events.…